Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Top Cited Papers
Open Access
- 22 October 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 52 (11) , 2864-2875
Abstract
Drug molecules consist of a few tens of atoms connected by covalent bonds. How many such molecules are possible in total and what is their structure? This question is of pressing interest in medicinal chemistry to help solve the problems of drug potency, selectivity, and toxicity and reduce attrition rates by pointing to new molecular series. To better define the unknown chemical space, we have enumerated 166.4 billion molecules of up to 17 atoms of C, N, O, S, and halogens forming the chemical universe database GDB-17, covering a size range containing many drugs and typical for lead compounds. GDB-17 contains millions of isomers of known drugs, including analogs with high shape similarity to the parent drug. Compared to known molecules in PubChem, GDB-17 molecules are much richer in nonaromatic heterocycles, quaternary centers, and stereoisomers, densely populate the third dimension in shape space, and represent many more scaffold types.Keywords
This publication has 44 references indexed in Scilit:
- Recent Trends and Observations in the Design of High-Quality Screening CollectionsFuture Medicinal Chemistry, 2011
- Molecular obesity, potency and other addictions in drug discoveryMedChemComm, 2011
- Chemical space as a source for new drugsMedChemComm, 2010
- Novel trends in high-throughput screeningCurrent Opinion in Pharmacology, 2009
- Efficient Drug Lead Discovery and OptimizationAccounts of Chemical Research, 2009
- Structural Diversity of Organic Chemistry. A Scaffold Analysis of the CAS RegistryThe Journal of Organic Chemistry, 2008
- Computer-based de novo design of drug-like moleculesNature Reviews Drug Discovery, 2005
- Small molecules: the missing link in the central dogmaNature Chemical Biology, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Hit and lead generation: beyond high-throughput screeningNature Reviews Drug Discovery, 2003